{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:20:25Z","timestamp":1788337225633,"version":"build-2803163510"},"reference-count":73,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"DHAC | National Health and Medical Research Council","award":["APP2010336"],"award-info":[{"award-number":["APP2010336"]}]},{"name":"DHAC | National Health and Medical Research Council","award":["APP1160379"],"award-info":[{"award-number":["APP1160379"]}]},{"name":"DHAC | National Health and Medical Research Council","award":["GNT1174091"],"award-info":[{"award-number":["GNT1174091"]}]},{"DOI":"10.13039\/501100001791","name":"Griffith University","doi-asserted-by":"crossref","award":["Internal Grant"],"award-info":[{"award-number":["Internal Grant"]}],"id":[{"id":"10.13039\/501100001791","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["mBio"],"published-print":{"date-parts":[[2025,4,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Acute rheumatic fever (ARF) is an autoimmune disease triggered by antibodies and T cells targeting the group A\n                      <jats:italic>Streptococcus<\/jats:italic>\n                      (GAS, Strep A) bacterium, often leading to rheumatic heart disease (RHD) and Sydenham\u2019s chorea. Long-term monthly penicillin injections are recognized as a cornerstone of public health programs to prevent Strep A reinfection and progression of ARF. However, compliance is poor, and better tools are required to slow disease progression. Preclinical evidence suggests that this can be achieved. Using a rat model that replicates post-streptococcal autoimmune complications, we explored the potential of low-dose interleukin-2 (LD-IL-2) as an immunotherapeutic intervention for ARF\/RHD. In this model, injections of recombinant M protein from Strep A type 5 (rM5) to Lewis rats induce cardiac tissue inflammation, conduction abnormalities, and cross-reactive antibodies against cardiac and brain proteins central to disease pathogenesis. In animals injected with rM5 and treated with LD-IL-2, no cardiac functional or histological changes was observed. LD-IL-2 therapy effectively reduced the production of cross-reactive antibodies raised against host proteins and significantly increased regulatory T cells in the mediastinal lymph nodes. These novel findings suggest that LD-IL-2 will be an effective immunotherapeutic agent for treating ARF and has the potential to replace the standard monthly penicillin injections.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>IMPORTANCE<\/jats:title>\n                    <jats:p>\n                      Post-streptococcal autoimmune syndromes, including acute rheumatic fever, rheumatic heart disease, and Sydenham\u2019s chorea, represent a significant yet often under-recognized health and economic burden. This is especially true in low-income countries and among Indigenous populations in high-income nations, where the disease burden is most severe. These conditions arise from an autoimmune response to group A\n                      <jats:italic>Streptococcus<\/jats:italic>\n                      infections, leading to long-term health complications, disability, and premature death. Despite their widespread impact, no vaccine is currently available to prevent reinfections, and no specific therapy exists to treat the resulting autoimmune process. This study uses a rat model of rheumatic heart disease to evaluate the potential of low-dose interleukin 2 therapy in improving clinical outcomes and reducing the incidence of autoimmune diseases triggered by streptococcal infections.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/mbio.03823-24","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T09:00:16Z","timestamp":1740474016000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":4,"title":["Low-dose interleukin 2 therapy halts the progression of post-streptococcal autoimmune complications in a rat model of rheumatic heart disease"],"prefix":"10.1128","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7190-9666","authenticated-orcid":false,"given":"Rukshan Ahamed Mohamed","family":"Rafeek","sequence":"first","affiliation":[{"name":"School of Science and Technology, University of New England","place":["New South Wales, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4870-706X","authenticated-orcid":false,"given":"Natkunam","family":"Ketheesan","sequence":"additional","affiliation":[{"name":"School of Science and Technology, University of New England","place":["New South Wales, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8212-248X","authenticated-orcid":true,"given":"Michael F.","family":"Good","sequence":"additional","affiliation":[{"name":"Institute for Biomedicine and Glycomics, Griffith University","place":["Gold Coast, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4151-699X","authenticated-orcid":false,"given":"Manisha","family":"Pandey","sequence":"additional","affiliation":[{"name":"School of Science and Technology, University of New England","place":["New South Wales, Australia"]},{"name":"Institute for Biomedicine and Glycomics, Griffith University","place":["Gold Coast, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1371-7313","authenticated-orcid":false,"given":"Ailin","family":"Lepletier","sequence":"additional","affiliation":[{"name":"School of Science and Technology, University of New England","place":["New South Wales, Australia"]},{"name":"Institute for Biomedicine and Glycomics, Griffith University","place":["Gold Coast, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603693"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0008095"},{"key":"e_1_3_3_4_2","unstructured":"Welfare AIoHa. 2022. Acute rheumatic fever and rheumatic heart disease in Australia 2016\u20132020. Australian Government catalogue number CVD 95. AIHW"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.gpp3-0045-2018"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.84"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix637"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.13.3.470"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20230558"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.05.028"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.2310\/JIM.0000000000000023"},{"key":"e_1_3_3_12_2","first-page":"118","article-title":"Regulatory T-cell deficiency in rheumatic heart disease: a preliminary observational study","volume":"22","author":"Mukhopadhyay S","year":"2013","unstructured":"Mukhopadhyay S, Varma S, Gade S, Yusuf J, Trehan V, Tyagi S. 2013. Regulatory T-cell deficiency in rheumatic heart disease: a preliminary observational study. J Heart Valve Dis 22:118\u2013125.","journal-title":"J Heart Valve Dis"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM195505122521901"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70113-X"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4148"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.41451"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-024-07165-2"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1359041"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105143"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009858"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2014.02.003"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.648408"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00171"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.1165"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.07.016"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/imcb.12571"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00604-2"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1080\/08916934.2019.1605356"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0896-8411(03)00026-x"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0120-4"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1334"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2010.08.004"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1080\/08916934.2016.1217999"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/jpc.16481"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0073516"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1267920"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.110558"},{"key":"e_1_3_3_38_2","first-page":"567","article-title":"Anticardiolipin antibodies in acute rheumatic fever and chronic rheumatic heart disease: is there a significant association?","volume":"14","author":"Narin N","year":"1996","unstructured":"Narin N, K\u00fct\u00fck\u00e7\u00fcler N, Narin F, Keser G, Doganavsargil E. 1996. Anticardiolipin antibodies in acute rheumatic fever and chronic rheumatic heart disease: is there a significant association? Clin Exp Rheumatol 14:567\u2013569.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37424-w"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1293"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.2217\/imt.14.83"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006577"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2022.100508"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.792135"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.62.6.2440-2449.1994"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/9.2.281"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/ame2.12164"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2014.00116"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2014.02.009"},{"key":"e_1_3_3_50_2","first-page":"22","article-title":"Therapeutic potential of ponesimod alone and in combination with dimethyl fumarate in experimental models of multiple sclerosis","volume":"16","author":"Pouzol L","year":"2019","unstructured":"Pouzol L, Piali L, Bernard CC, Martinic MM, Steiner B, Clozel M. 2019. Therapeutic potential of ponesimod alone and in combination with dimethyl fumarate in experimental models of multiple sclerosis. Innov Clin Neurosci 16:22\u201330.","journal-title":"Innov Clin Neurosci"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpns.36"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2018.02.003"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12812"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.764786"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800793"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2012.04133.x"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2010.03.006"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200030"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/3758713"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1002416"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2011.03529.x"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.2.677"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.179.1.57"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28335-3"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells9092063"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)80067-o"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-3347"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103186"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.08.035"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.134.1.157"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023009729"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01514-08"},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173778"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2010.02.013"}],"container-title":["mBio"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/mbio.03823-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/mbio.03823-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T09:03:55Z","timestamp":1744189435000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/mbio.03823-24"}},"subtitle":[],"editor":[{"given":"Stefan H. E.","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":73,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,9]]}},"alternative-id":["10.1128\/mbio.03823-24"],"URL":"https:\/\/doi.org\/10.1128\/mbio.03823-24","relation":{},"ISSN":["2150-7511"],"issn-type":[{"value":"2150-7511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"2024-12-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e03823-24"}}